65,437 trials
Psoriasis
Primary: Number of Therapies That Were Applied as Induction, Maintenance, or Episodic Therapies After One Infusion of Infliximab — 7; 2; 1; 2 Therapies
Appendicitis
Primary: Negative Appendectomy — 6; 6; 166; 180 participants
Asthma
Primary: Number of Symptom-free Days Over Two Weeks — 10.79; 8.71; 12.89 Days
Hypertension
Primary: Serum Uric Acid (SUA) Level — 6.4; 6.6 mg/dL — p=<0.01
Influenza
Primary: Geometric Mean Titer 21 Days After the Study Vaccination — 58.60; 58.45; 377.94; 337.23 Titers
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-IV) Parent Version: Investigator Administered and Scored - Total Score at Week 10…
Prostate Cancer
Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants
Head and Neck Cancer · Pharynx Cancer
Primary: Tumor Resolution — 25 Participants
Leukemia, Myelocytic, Acute Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 participants
Coronary Artery Disease · Myocardial Ischemia
Primary: Number of Participants With Target Vessel Failure (TVF) at 30 Days Post Procedure. — 2 Participants
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 5.5 months — p=<0.0001
Chronic Obstructive Pulmonary Disease
Primary: Inspiratory Capacity (IC) at Peak Time and at Isotime on Day 14 — 2.36; 2.05; 2.37; 2.10 Liters
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 401.655; 360.619 hr*ng/mL
Transitional Cell Carcinoma of Bladder · Superficial Bladder Cancer
Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)
Infertility
Primary: Percentage of Participants With Ongoing Pregnancy at Week 8 — 45.2; 45.2; 42.9; 48.7 percentage of participants